AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/101
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors
Authors: Hartmann, JT Fossa, SD Nichols, CR Droz, JP Horwich, A Gerl, A Beyer, J Pont, J Fizazi, K Hecker, H Kanz, L Einhorn, L Bokemeyer, C
Citation: Jt. Hartmann et al., Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors, J NAT CANC, 93(22), 2001, pp. 1733-1738
Comparison of (18)FDG-PET with CT scans in the evaluation of patients withresidual and recurrent Hodgkin's lymphoma
Authors: Dittmann, H Sokler, M Kollmannsberger, C Dohmen, BM Baumann, C Kopp, A Bares, R Claussen, CD Kanz, L Bokemeyer, C
Citation: H. Dittmann et al., Comparison of (18)FDG-PET with CT scans in the evaluation of patients withresidual and recurrent Hodgkin's lymphoma, ONCOL REP, 8(6), 2001, pp. 1393-1399
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis
Authors: Hartmann, JT Einhorn, L Nichols, CR Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Schmoll, HJ Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis, J CL ONCOL, 19(6), 2001, pp. 1641-1648
Clinical impact of germ cell tumor cells in apheresis products of patientsreceiving high-dose chemotherapy
Authors: Bokemeyer, C Gillis, AJM Pompe, K Mayer, F Metzner, B Schleucher, N Schleicher, J Pflugrad-Jauch, G Oosterhuis, JW Kanz, L Looijenga, LHJ
Citation: C. Bokemeyer et al., Clinical impact of germ cell tumor cells in apheresis products of patientsreceiving high-dose chemotherapy, J CL ONCOL, 19(12), 2001, pp. 3029-3036
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer
Authors: Rick, O Bokemeyer, C Beyer, J Hartmann, JT Schwella, N Kingreen, D Neureither, S Metzner, B Casper, J Wandt, H Hartmann, F Schmoll, HJ Derigs, G Gerl, A Berdel, WE Kanz, L Siegert, W
Citation: O. Rick et al., Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer, J CL ONCOL, 19(1), 2001, pp. 81-88
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy
Authors: Kollmannsberger, C Mayer, F Kuczyk, M Kanz, L Bokemeyer, C
Citation: C. Kollmannsberger et al., Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy, WORLD J URO, 19(2), 2001, pp. 120-125
Dendritic cells in cancer vaccines
Authors: Brossart, P Wirths, S Brugger, W Kanz, L
Citation: P. Brossart et al., Dendritic cells in cancer vaccines, EXP HEMATOL, 29(11), 2001, pp. 1247-1255
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant
Authors: Hebart, H Wuchter, P Loeffler, J Gscheidle, B Hamprecht, K Sinzger, C Jahn, G Dietz, K Kanz, L Einsele, H
Citation: H. Hebart et al., Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant, BONE MAR TR, 28(2), 2001, pp. 213-218
Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: New insights through latent membrane protein 1 fingerprinting
Authors: Schafer, H Berger, C Aepinus, C Hebart, H Beck, R Kaiserling, E Kanz, L Einsele, H Knecht, H
Citation: H. Schafer et al., Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: New insights through latent membrane protein 1 fingerprinting, TRANSPLANT, 72(3), 2001, pp. 492-496
Retraction: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (vol 333, pg 283, 1995)
Authors: Kanz, L Brugger, W
Citation: L. Kanz et W. Brugger, Retraction: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (vol 333, pg 283, 1995), N ENG J MED, 345(1), 2001, pp. 64-64
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes
Authors: Brossart, P Schneider, A Dill, P Schammann, T Grunebach, F Wirths, S Kanz, L Buhring, HJ Brugger, W
Citation: P. Brossart et al., The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes, CANCER RES, 61(18), 2001, pp. 6846-6850
Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome
Authors: Bokemeyer, C Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Schmoll, HJ Kanz, L Einhorn, L Nichols, CR Hartmann, JT
Citation: C. Bokemeyer et al., Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome, CANCER, 91(7), 2001, pp. 1394-1401
Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment
Authors: Herrlinger, U Schabet, M Brugger, W Kortmann, RD Kanz, L Bamberg, M Dichgans, J Weller, M
Citation: U. Herrlinger et al., Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment, CANC CYTOP, 91(1), 2001, pp. 130-135
Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment
Authors: Herrlinger, U Schabet, M Brugger, W Kortmann, RD Kanz, L Bamberg, M Dichgans, J Weller, M
Citation: U. Herrlinger et al., Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment, CANCER, 91(1), 2001, pp. 130-135
High-grade lymphoma mimicking bone crisis in Gaucher's disease
Authors: Manz, M Riessen, R Poll, L Dohmen, B Kaiserling, E Kruck, W Laniado, M Kanz, L Denzlinger, C
Citation: M. Manz et al., High-grade lymphoma mimicking bone crisis in Gaucher's disease, BR J HAEM, 113(1), 2001, pp. 191-193
Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells
Authors: Kleihauer, A Grigoleit, U Hebart, H Moris, A Brossart, P Muhm, A Stevanovic, S Rammensee, HG Sinzger, C Riegler, S Jahn, G Kanz, L Einsele, H
Citation: A. Kleihauer et al., Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells, BR J HAEM, 113(1), 2001, pp. 231-239
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation
Authors: Hartmann, JT von Vangerow, A Fels, LM Knop, S Stolte, H Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation, BR J CANC, 84(3), 2001, pp. 313-320
Signal-regulatory protein alpha (SIRP alpha) but not SIRP beta is involvedin T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells
Authors: Seiffert, M Brossart, P Cant, C Cella, M Colonna, M Brugger, W Kanz, L Ullrich, A Buhring, HJ
Citation: M. Seiffert et al., Signal-regulatory protein alpha (SIRP alpha) but not SIRP beta is involvedin T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells, BLOOD, 97(9), 2001, pp. 2741-2749
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
Authors: Hebart, H Brugger, W Grigoleit, U Gscheidle, B Loeffler, J Schafer, H Kanz, L Einsele, H Sinzger, C
Citation: H. Hebart et al., Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality, BLOOD, 97(7), 2001, pp. 2183-2185
Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1
Authors: Bautz, F Denzlinger, C Kanz, L Mohle, R
Citation: F. Bautz et al., Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1, BLOOD, 97(11), 2001, pp. 3433-3440
The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3
Authors: Buhring, HJ Seiffert, M Giesert, C Marxer, A Kanz, L Valent, P Sano, K
Citation: Hj. Buhring et al., The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3, BLOOD, 97(10), 2001, pp. 3303-3305
HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatmentwith cyclosporin A, azathioprine, and prednisolone for ocular Behcet's disease and complete remission of both disorders with interferon alpha
Authors: Kotter, I Aepinus, C Graepler, F Gartner, V Eckstein, AK Stubiger, N Kaskas, B Zierhut, M Bultmann, B Kandolf, R Kanz, L
Citation: I. Kotter et al., HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatmentwith cyclosporin A, azathioprine, and prednisolone for ocular Behcet's disease and complete remission of both disorders with interferon alpha, ANN RHEUM D, 60(1), 2001, pp. 83-86
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors
Authors: Hartmann, JT Nichols, CR Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Fizazi, K Einhorn, L Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors, J NAT CANC, 92(1), 2000, pp. 54-61
Regression of human metastatic renal cell carcinoma after vaccination withtumor cell-dendritic cell hybrids
Authors: Kugler, A Stuhler, G Walden, P Zoller, G Zobywalski, A Brossart, P Trefzer, U Ullrich, S Muller, CA Becker, V Gross, AJ Hemmerlein, B Kanz, L Muller, GA Ringert, RH
Citation: A. Kugler et al., Regression of human metastatic renal cell carcinoma after vaccination withtumor cell-dendritic cell hybrids, NAT MED, 6(3), 2000, pp. 332-336
Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC)
Authors: Vogel, W Scheding, S Kanz, L Brugger, W
Citation: W. Vogel et al., Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC), STEM CELLS, 18(2), 2000, pp. 87-92
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>